Mink Therapeutics (INKT) Q3 2024 earnings summary

Executive summary

• Advanced allogeneic iNKT cell therapy platform for solid tumors and immune-related diseases, with ongoing Phase 2 trial in gastric cancer and new research collaborations.

• Lead candidate agenT-797 is in Phase 2 for gastric cancer and viral ARDS, with promising Phase 1 results in solid tumors and ARDS.

• Welcomed Dr. Robert Kadlec to the board, strengthening expertise in public health and biodefense.

• Pipeline includes next-gen engineered iNKT programs and collaborations for TCR discovery and metastatic tumor therapies.

• Focused on financial discipline, cost containment, and operational efficiency.

Financial highlights

• Ended Q3 2024 with $6.3 million in cash, up from $3.4 million at year-end 2023.

• Net loss for Q3 2024 was $1.8 million ($0.05/share), and $8.3 million ($0.22/share) for the nine months, both significantly reduced year-over-year.

• Cash used in operations for the nine months was $7.8 million, down from $12.7 million in the prior year period.

• R&D expenses fell 84% year-over-year for Q3, mainly due to a $1.8 million gain from liability forgiveness and lower clinical activity.

• General and administrative expenses decreased 35% in Q3, reflecting reduced personnel and share-based compensation costs.

Outlook and guidance

• Phase 2 trial in advanced gastric cancer is nearly halfway enrolled, with data updates expected at a major oncology conference in early 2025.

• Enrollment for the gastric cancer trial expected to complete by mid-2025.

• Phase 1 GvHD trial with external funding to begin dosing in 2025.

• Management expects continued operating losses and negative cash flows until commercialization or substantial partnerships are achieved.

• Additional funding will be sought through partnerships, non-dilutive financing, or equity/debt offerings.